These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32830288)

  • 1. GDNF clinical trials for Parkinson's disease: a critical human dimension.
    Gash DM; Gerhardt GA; Bradley LH; Wagner R; Slevin JT
    Cell Tissue Res; 2020 Oct; 382(1):65-70. PubMed ID: 32830288
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDNF delivery for Parkinson's disease.
    Patel NK; Gill SS
    Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
    Lindvall O; Wahlberg LU
    Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease.
    Terse PS; Kells AP; Noker P; Wright JF; Bankiewicz KS
    Int J Toxicol; 2021; 40(1):4-14. PubMed ID: 33131343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
    Yasuhara T; Shingo T; Date I
    Acta Med Okayama; 2007 Apr; 61(2):51-6. PubMed ID: 17471304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.
    Kordower JH; Palfi S; Chen EY; Ma SY; Sendera T; Cochran EJ; Cochran EJ; Mufson EJ; Penn R; Goetz CG; Comella CD
    Ann Neurol; 1999 Sep; 46(3):419-24. PubMed ID: 10482276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats.
    Grandoso L; Ponce S; Manuel I; Arrúe A; Ruiz-Ortega JA; Ulibarri I; Orive G; Hernández RM; Rodríguez A; Rodríguez-Puertas R; Zumárraga M; Linazasoro G; Pedraz JL; Ugedo L
    Int J Pharm; 2007 Oct; 343(1-2):69-78. PubMed ID: 17583454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preservation of brain cells in Parkinson disease].
    Aasly JO
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):894. PubMed ID: 16554876
    [No Abstract]   [Full Text] [Related]  

  • 12. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
    Du Y; Zhang X; Tao Q; Chen S; Le W
    Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crossroads in GDNF therapy for Parkinson's disease.
    Sherer TB; Fiske BK; Svendsen CN; Lang AE; Langston JW
    Mov Disord; 2006 Feb; 21(2):136-41. PubMed ID: 16470786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized striatal delivery of GDNF as a treatment for Parkinson disease.
    Kirik D; Georgievska B; Björklund A
    Nat Neurosci; 2004 Feb; 7(2):105-10. PubMed ID: 14747832
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.
    Herrán E; Ruiz-Ortega JÁ; Aristieta A; Igartua M; Requejo C; Lafuente JV; Ugedo L; Pedraz JL; Hernández RM
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1183-90. PubMed ID: 23639739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Delivery for Movement Disorders.
    Barua N; Gill S
    Prog Neurol Surg; 2018; 33():243-252. PubMed ID: 29332088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease.
    Lapchak PA; Gash DM; Collins F; Hilt D; Miller PJ; Araujo DM
    Exp Neurol; 1997 Jun; 145(2 Pt 1):309-21. PubMed ID: 9217068
    [No Abstract]   [Full Text] [Related]  

  • 18. [Growth factors as neuroprotective treatment in Parkinson disease?].
    Torp R; Singh PB; Sørensen DR; Dietrichs E; Hirschberg H
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):899-901. PubMed ID: 16554879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease.
    Lapchak PA; Miller PJ; Jiao S; Araujo DM; Hilt D; Collins F
    Neurodegeneration; 1996 Sep; 5(3):197-205. PubMed ID: 8910897
    [No Abstract]   [Full Text] [Related]  

  • 20. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
    Grondin R; Gash DM
    J Neurol; 1998 Nov; 245(11 Suppl 3):P35-42. PubMed ID: 9808338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.